Hyloris Pharmaceuticals SA (HYL.BR)

EUR 6.48

(-0.34%)

Net Income Summary of Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA's latest annual net income in 2023 was -15.38 Million EUR , down -42.8% from previous year.
Hyloris Pharmaceuticals SA's latest quarterly net income in 2023 FY was -15.38 Million EUR , down -42.8% from previous quarter.
Hyloris Pharmaceuticals SA reported an annual net income of -10.77 Million EUR in 2022, up 6.99% from previous year.
Hyloris Pharmaceuticals SA reported an annual net income of -11.57 Million EUR in 2021, down -62.03% from previous year.
Hyloris Pharmaceuticals SA reported a quarterly net income of -4.37 Million EUR for 2023 Q3, down -31.84% from previous quarter.
Hyloris Pharmaceuticals SA reported a quarterly net income of -3.31 Million EUR for 2023 Q1, up 4.74% from previous quarter.

Annual Net Income Chart of Hyloris Pharmaceuticals SA (2023 - 2017)

Historical Annual Net Income of Hyloris Pharmaceuticals SA (2023 - 2017)

Year	Net Income	Net Income Growth
2023	-15.38 Million EUR	-42.8%
2022	-10.77 Million EUR	6.99%
2021	-11.57 Million EUR	-62.03%
2020	-7.14 Million EUR	-23.89%
2019	-5.76 Million EUR	0.4%
2018	-5.79 Million EUR	-55.8%
2017	-3.71 Million EUR	0.0%

Year	Net Income	Net Income Growth
2023 Q2	-3.31 Million EUR	0.0%
2023 Q3	-4.37 Million EUR	-31.84%
2023 Q1	-3.31 Million EUR	4.74%
2023 FY	-15.38 Million EUR	-42.8%
2023 Q4	-4.37 Million EUR	0.0%
2022 Q2	-4.94 Million EUR	-100.0%
2022 FY	-10.77 Million EUR	6.99%
2022 Q4	-3.48 Million EUR	0.0%
2022 Q3	-3.48 Million EUR	29.54%
2022 Q1	-2.47 Million EUR	26.0%
2021 FY	-11.57 Million EUR	-62.03%
2021 Q4	-3.33 Million EUR	-100.0%
2021 Q3	-1.66 Million EUR	79.74%
2021 Q2	-8.24 Million EUR	-100.0%
2021 Q1	-4.12 Million EUR	-142.14%
2020 Q2	-2.63 Million EUR	-66.96%
2020 FY	-7.14 Million EUR	-23.89%
2020 Q4	-1.7 Million EUR	0.0%
2020 Q1	-1.58 Million EUR	26.43%
2020 Q3	-1.7 Million EUR	35.5%
2019 Q2	-580 Thousand EUR	16.06%
2019 Q3	-2.14 Million EUR	-270.26%
2019 Q1	-691 Thousand EUR	0.0%
2019 FY	-5.76 Million EUR	0.4%
2019 Q4	-2.14 Million EUR	0.0%
2018 FY	-5.79 Million EUR	-55.8%
2017 FY	-3.71 Million EUR	0.0%

Peer Net Income Comparison of Hyloris Pharmaceuticals SA

Name	Net Income	Net Income Difference
Nicox S.A.	-20.88 Million EUR	26.345%
European Medical Solutions	-709 Thousand EUR	-2069.252%
FERMENTALG	-14.14 Million EUR	-8.708%
argenx SE	-272.91 Million EUR	94.365%
BioSenic S.A.	-28.77 Million EUR	46.556%
Celyad Oncology SA	-8.44 Million EUR	-82.055%
Onward Medical N.V.	-36.18 Million EUR	57.492%
Oxurion NV	-18.96 Million EUR	18.92%
PHAXIAM Therapeutics S.A.	-23.48 Million EUR	34.52%
Financière de Tubize SA	88.15 Million EUR	117.447%
UCB SA	343 Million EUR	104.484%